EFL创始人，浙大贺永教授：生物3D打印机赋能器官模型构建与器官体外再造

Core Viewpoint - EFL is focused on the development and application of bioprinting technologies, particularly in regenerative medicine, showcasing its innovations at the upcoming 2025 Polymer 3D Printing Materials Summit [1][21]. Company Overview - EFL was established in 2017, leveraging research outcomes from Zhejiang University led by Professor He Yong [2]. - The company provides comprehensive services in regenerative medicine, encompassing scientific popularization, research services, and technology transfer [3]. Product Offerings - EFL offers several advanced products: - Volume Photopolymerization Bioprinter: Capable of rapid formation of cell-laden hydrogel structures with a 4K projection accuracy [4]. - Multi-functional Extrusion Bioprinter: Features a wide temperature control range of -25 to 260°C, suitable for various bioprinting materials [8]. - Projection Photopolymerization Bioprinter: Supports automatic switching of up to six inks for complex bioprinting needs [12]. - Microneedle Manufacturing Device: The first multifunctional desktop device for preparing hydrogel microneedles, integrating humidity and vacuum control systems [17]. - Gelatin Methacryloyl (GelMA): A versatile hydrogel with excellent biocompatibility and mechanical properties, suitable for 3D cell culture and tissue engineering [19]. Technical Highlights - The bioprinters boast high printing speeds, with structures forming in seconds, and maintain a cell viability rate exceeding 95% [5][9][13]. - The devices are designed for various applications, including cell culture scaffolds, organoids, and organ-on-a-chip technologies [5][9][13]. Market Position - EFL ranks among the top three in the domestic bioprinting research market, with its photopolymerization bioprinting inks holding the leading market share [6][10][14].